Healthcare stocks as a group have not performed on par with broader equities this year. However, that doesn't mean investors ...

Drug development in biotechnology takes time. A lot of time. On average, it takes 10 to 15 years to take a medicine from ...

From rare diseases to chronic conditions, epigenetic editing unlocks new ways to control gene activity without altering the genetic code.

Chicago-based CRISPR technology company Syntax Bio says it has developed tech which automates the slow, manual process of ...

MUTE-Seq is a new liquid-biopsy method powered by an engineered ultra-precise CRISPR enzyme, FnCas9-AF2, which can ...

Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its ...

Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its ...

A team of researchers at the Icahn School of Medicine at Mount Sinai has uncovered why children with the same ...

To the research team working to save him, KJ Muldoon was first known only as Patient Eta. But within months, KJ’s name — and ...

This year, gene-editing technology was customized to fix mutations in a single patient’s genes for the first time.

The United States DNA polymerase market is projected to reach USD 246.9 million by 2035, supported by rising investments in ...

The problem, Zaaijer explained, is that algorithms used in precision medicine models overwhelming are built on DNA with ...